-transparent.png){kind=logo}
Cimetidine 200 mg three times daily and 400 mg at night was given to 10 subjects for four weeks. Apparent liver blood flow was measured by indocyanine green clearance and microsomal enzyme activity by antipyrine clearance, before and after cimetidine. There was no reduction in indocyanine green clearance but antipyrine clearance, as expected, was significantly reduced by 15% at four weeks. Chronic cimetidine treatment does not reduce apparent liver blood flow and is therefore unlikely to be of use in the treatment of portal hypertension. The cimetidine associated hepatic enzyme inhibition appears to persist with prolonged treatment. Therefore patients on chronic cimetidine remain vulnerable to certain drug interactions.
T K Daneshmend, and
M D Ene, and
G Parker, and
C J Roberts
July 1984,
Gut,
T K Daneshmend, and
M D Ene, and
G Parker, and
C J Roberts
September 1976,
Biochemical pharmacology,
T K Daneshmend, and
M D Ene, and
G Parker, and
C J Roberts
February 1979,
Life sciences,
T K Daneshmend, and
M D Ene, and
G Parker, and
C J Roberts
January 1978,
Biochemical pharmacology,
T K Daneshmend, and
M D Ene, and
G Parker, and
C J Roberts
January 1983,
European journal of clinical pharmacology,
T K Daneshmend, and
M D Ene, and
G Parker, and
C J Roberts
May 1984,
The American journal of medicine,
T K Daneshmend, and
M D Ene, and
G Parker, and
C J Roberts
January 1983,
Acta chirurgica Scandinavica,
T K Daneshmend, and
M D Ene, and
G Parker, and
C J Roberts
September 1979,
Biochemical pharmacology,
T K Daneshmend, and
M D Ene, and
G Parker, and
C J Roberts
April 1979,
Biochemical pharmacology,
T K Daneshmend, and
M D Ene, and
G Parker, and
C J Roberts
August 1983,
British journal of clinical pharmacology,
